ATE360082T1 - Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber - Google Patents
Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leberInfo
- Publication number
- ATE360082T1 ATE360082T1 AT00982132T AT00982132T ATE360082T1 AT E360082 T1 ATE360082 T1 AT E360082T1 AT 00982132 T AT00982132 T AT 00982132T AT 00982132 T AT00982132 T AT 00982132T AT E360082 T1 ATE360082 T1 AT E360082T1
- Authority
- AT
- Austria
- Prior art keywords
- liver
- transgenes
- vectors
- regulatory elements
- elements
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16586699P | 1999-11-16 | 1999-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE360082T1 true ATE360082T1 (de) | 2007-05-15 |
Family
ID=22600808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00982132T ATE360082T1 (de) | 1999-11-16 | 2000-11-15 | Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber |
Country Status (7)
Country | Link |
---|---|
US (2) | US7312324B2 (de) |
EP (2) | EP1232276B8 (de) |
AT (1) | ATE360082T1 (de) |
AU (1) | AU1920201A (de) |
DE (1) | DE60034478T2 (de) |
ES (1) | ES2284545T3 (de) |
WO (1) | WO2001036620A2 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
AU2003223775A1 (en) * | 2002-04-30 | 2003-11-17 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
SI3404102T1 (sl) | 2004-04-21 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti |
US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
TWI293307B (en) | 2004-09-30 | 2008-02-11 | Ind Tech Res Inst | A liver-specific chimeric regulatory sequence and use thereof |
MX360595B (es) | 2006-02-08 | 2018-11-09 | Genzyme Corp | Terapia génica para la enfermedad de niemann-pick de tipo a. |
PT2662448T (pt) | 2007-05-11 | 2017-03-29 | Alexion Pharma Inc | Fosfatase alcalina dirigida ao osso, kits e métodos para a utilização da mesma |
DK2282764T3 (da) * | 2008-04-22 | 2019-10-14 | Vib Vzw | Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf |
SI2889043T1 (sl) | 2008-12-16 | 2019-08-30 | Genzyme Corporation | Sintetične vmesne spojine za pripravo konjugatov oligosaharid-protein |
CN103153344A (zh) | 2010-04-30 | 2013-06-12 | 阿莱克森国际制药有限公司 | 用于治疗基质矿化障碍的方法、组合物、和试剂盒 |
WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
SG11201401605QA (en) | 2011-10-19 | 2014-09-26 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
MX2017007392A (es) | 2014-12-05 | 2019-01-24 | Alexion Pharma Inc | Tratamiento de convulsiones con fosfatasa alcalina recombinante. |
EP3250227A2 (de) | 2015-01-28 | 2017-12-06 | Alexion Pharmaceuticals, Inc. | Verfahren zur behandlung eines patienten mit mangel an alkalischer phosphatase |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
RU2745528C2 (ru) | 2015-08-17 | 2021-03-26 | Алексион Фармасьютикалз, Инк. | Производство щелочных фосфатаз |
US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
RU2754558C2 (ru) | 2016-04-01 | 2021-09-03 | Алексион Фармасьютикалз, Инк. | Лечение мышечной слабости с помощью щелочных фосфатаз |
EP3436020A4 (de) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | Verfahren zur behandlung von hypophosphatasie bei jugendlichen und erwachsenen |
PE20181922A1 (es) | 2016-04-15 | 2018-12-11 | Univ Pennsylvania | Terapia genica para tratar la hemofilia a |
WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 気管気管支軟化症の治療方法 |
KR20190129058A (ko) | 2017-03-31 | 2019-11-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법 |
CA3057142A1 (en) | 2017-04-03 | 2018-10-11 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
WO2018213786A1 (en) * | 2017-05-19 | 2018-11-22 | Encoded Therapeutics, Inc. | High activity regulatory elements |
AU2018345745A1 (en) * | 2017-10-02 | 2020-04-30 | American Gene Technologies International Inc. | Vectors with promoter and enhancer combinations for treating phenylketonuria |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
EP3755795A4 (de) | 2018-02-19 | 2022-07-20 | Homology Medicines, Inc. | Adeno-assoziierte viruszusammensetzungen zur wiederherstellung der f8-genfunktion und verfahren zur verwendung davon |
WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
WO2020081979A1 (en) * | 2018-10-19 | 2020-04-23 | Memorial Sloan-Kettering Cancer Center | Low dose radiation conditioning for immunotherapy |
WO2020102723A1 (en) * | 2018-11-16 | 2020-05-22 | Encoded Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
CN116096732A (zh) | 2020-01-31 | 2023-05-09 | 贝斯以色列护理医疗中心有限公司 | 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗 |
CN111088282B (zh) * | 2020-03-23 | 2020-08-28 | 上海安民生物技术有限公司 | Aavs1和h11安全港位点在重组表达蛋白中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1265794B1 (it) * | 1992-09-07 | 1996-12-03 | Angeletti P Ist Richerche Bio | Mammiferi transgenici non umani con un oncogene sotto il controllo di un promotore inducibile fegato-specifico |
DE4339922C1 (de) * | 1993-09-03 | 1994-10-06 | Max Planck Gesellschaft | Vektor für Leber-Gentherapie |
US6268212B1 (en) * | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
DE4407859C1 (de) * | 1994-03-04 | 1995-03-02 | Max Planck Gesellschaft | Vektor für die leberspezifische Gentherapie |
US5965541A (en) * | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
DE19525900C1 (de) * | 1995-07-15 | 1996-12-12 | Max Planck Gesellschaft | Leberspezifischer Adenovirus-Expressionsvektor |
EP0933997A4 (de) * | 1996-09-06 | 2000-08-16 | Chiron Corp | Verfahren und zusammensetzungen für die leberspezifische verabreichung von therapeutischen molekülen unter verwendung rekombinanter aav vektoren |
US20020155095A1 (en) * | 1996-10-18 | 2002-10-24 | Tattanahalli L. Nagabhushan | Methods and compositions for delivery and expression of interferon-a nucleic acids |
AU735763B2 (en) * | 1997-12-05 | 2001-07-12 | Immune Response Corporation, The | Novel vectors and genes exhibiting increased expression |
AU2231099A (en) * | 1998-01-16 | 1999-08-02 | Genzyme Corporation | Novel promoter elements for persistent gene expression |
-
2000
- 2000-11-15 ES ES00982132T patent/ES2284545T3/es not_active Expired - Lifetime
- 2000-11-15 AT AT00982132T patent/ATE360082T1/de active
- 2000-11-15 AU AU19202/01A patent/AU1920201A/en not_active Abandoned
- 2000-11-15 EP EP00982132A patent/EP1232276B8/de not_active Expired - Lifetime
- 2000-11-15 DE DE60034478T patent/DE60034478T2/de not_active Expired - Lifetime
- 2000-11-15 WO PCT/US2000/031444 patent/WO2001036620A2/en active IP Right Grant
- 2000-11-15 EP EP07007344A patent/EP1818407A3/de not_active Withdrawn
-
2002
- 2002-05-06 US US10/139,763 patent/US7312324B2/en not_active Expired - Lifetime
-
2007
- 2007-11-13 US US11/938,906 patent/US20080070297A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080070297A1 (en) | 2008-03-20 |
DE60034478D1 (de) | 2007-05-31 |
DE60034478T2 (de) | 2008-01-10 |
US7312324B2 (en) | 2007-12-25 |
US20030017139A1 (en) | 2003-01-23 |
EP1818407A2 (de) | 2007-08-15 |
EP1232276A2 (de) | 2002-08-21 |
ES2284545T3 (es) | 2007-11-16 |
EP1232276B1 (de) | 2007-04-18 |
WO2001036620A2 (en) | 2001-05-25 |
AU1920201A (en) | 2001-05-30 |
EP1818407A3 (de) | 2007-08-29 |
EP1232276B8 (de) | 2007-06-27 |
WO2001036620A3 (en) | 2002-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE360082T1 (de) | Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber | |
ATE310817T1 (de) | Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine | |
DE69838249D1 (de) | Anti-apo-2 antikörper | |
ES8500322A1 (es) | Un metodo de modificar un virus para conferirle una nueva funcion biologica. | |
DK1240337T3 (da) | Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser | |
HK1022700A1 (en) | Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained | |
DE68929430D1 (de) | Fibronektin bindendes Protein | |
NO951641D0 (no) | Transkripsjonsfaktor | |
EP0845530A3 (de) | Interferon gamma induzierender Faktor | |
EP1368467A4 (de) | Putrescin-n-methyltransferasepromotor | |
DE69839489D1 (de) | Impfstoff zur vorbeugung bzw. behandlung der hepatitis c | |
ATE223481T1 (de) | Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator | |
ATE349225T1 (de) | Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv | |
HK1038572A1 (en) | Growth differentiation factor promoter and uses therefor | |
DE60024658D1 (de) | Promotor zur regulierung von fremdgenexpression | |
DE68924464D1 (de) | Interferon-gamma bindende Proteine. | |
ES2076178T3 (es) | Papilomavirus humano tipo 57, su adn y las proteinas codificadas por el. | |
DE69229356T2 (de) | NEUE VERBESSERUNGEN hinsichtlich der RADIOMARKIERUNG von PROTEINEn | |
WO2001059108A3 (en) | Inhibitors of apoptosis | |
AU551228B2 (en) | N-sulphenylated benzyl sulphonamides | |
DE59809249D1 (de) | Vektor zur Expression von Immunglobulin-zytokin-Fusionsproteinen in malignen-B-Zellen | |
ATE321776T1 (de) | Pna-konjugat zur therapie der chronischen myeloischen leukämie (cml) | |
ATE210667T1 (de) | Strobilurinanalogverbindungen mit fungiziden eigenschaften und ihre verwendung zur bekämpfung von phytopathogenen pilzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1232276 Country of ref document: EP |